Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected in Bulgaria
Abstract number: R2171
Objectives: Daptomycin is a cyclic lipopeptide with potent activity and broad spectrum against Gram-positive bacteria currently used for the treatment of complicated skin and skin structure infections and bacteremia, including right sided endocarditis. We evaluated the in vitro activity of this new compound against clinical strains of staphylococci and enterococci collected from Bulgarian medical centers in the National Reference Laboratory for "Control and Monitoring of Antimicrobial Resistance" at the National Center of Infectious and Parasitic Diseases, Sofia.
Methods: A total of 100 fresh, non-duplicate clinical strains, including 60 Staphylococcus aureus (MRSA), 40 Enterococcus spp. (20 Enterococcus faecium, 15 E. faecalis and 5 E. avium) from different medical centers were tested for susceptibility by reference agar microdilution methods according to Clinical and Laboratory Standards Institute guidelines and interpretative criteria.
Results: All S. aureus strains were inhibited at a daptomycin MIC of 1 mg/l. Among tested E. faecium strains the highest daptomycin MIC value was 2 mg/l (MIC50 under 0.5 mg/l), while among E. faecalis and E. avium the highest MIC value was 1 mg/l (Table 1).
Conclusion: Daptomycin showed excellent in vitro activity against staphylococci and enterococci collected in the National Reference Laboratory for "Control and Monitoring of Antimicrobial Resistance" and appears to be an excellent therapeutic option for serious infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci. During this National study no resistant bacteria were found in Bulgaria and 100% of the tested strains were susceptible to Daptomycin.
|Session name:||Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases|
|Location:||Vienna, Austria, 10 - 13 April 2010|
|Back to top|